Elia Seguí/clinicbarcelona.org
May 16, 2025, 17:04
Elia Seguí: Happy to have presented today at ESMO Breast 2025 our work on TLS in breast cancer
Elia Seguí, Research Fellow – Breast Oncology at Dana-Farber Cancer Institute, shared on LinkedIn:
“Super happy to have presented today at ESMO Breast 2025 our work on tertiary lymphoid structures (TLS) in breast cancer!
- The role of B cells is gaining momentum in cancer immunology, and TLS are emerging as key players in the tumor microenvironment—driving adaptive antitumor immune responses.
- Over the past few years, Esther Sanfeliu has been deeply focused on TLS and has developed a novel H&E-based scoring system that accounts for both TLS maturity (presence of a germinal center) and TLS count in the stroma.
- Gene expression analysis revealed a continuous immune activation gradient, with increasing B-cell and T-cell activation across TLS categories.
- This H&E-based scoring system enables structured TLS assessment and might provide biological insights beyond TILs.
A collaboration between, Hospital Clínic of Barcelona, the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), SOLTI cancer research and Reveal Genomics, S.L.
Huge thanks to all the coauthors who made this work possible.”
More posts featuring ESMO Breast 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 16, 2025, 16:47
May 16, 2025, 16:35
May 16, 2025, 16:18
May 16, 2025, 15:30